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Human Zika infection induces a 
reduction of IFN-γ producing CD4 
T-cells and a parallel expansion of 
effector Vδ2 T-cells
Eleonora Cimini1, Concetta Castilletti  2, Alessandra Sacchi1, Rita Casetti1, Veronica Bordoni1, 
Antonella Romanelli1, Federica Turchi1, Federico Martini1, Nicola Tumino1, Emanuele 
Nicastri3, Angela Corpolongo3, Antonino Di Caro  2, Gary Kobinger4, Alimuddin Zumla5, 
Maria Rosaria Capobianchi2, Giuseppe Ippolito6 & Chiara Agrati1
The definition of the immunological response to Zika (ZIKV) infection in humans represents a key 
issue to identify protective profile useful for vaccine development and for pathogenesis studies. No 
data are available on the cellular immune response in the acute phase of human ZIKV infection, and 
its role in the protection and/or pathogenesis needs to be clarified. We studied and compared the 
phenotype and functionality of T-cells in patients with acute ZIKV and Dengue viral (DENV) infections. 
A significant activation of T-cells was observed during both ZIKV and DENV infections. ZIKV infection 
was characterized by a CD4 T cell differentiation toward effector cells and by a lower frequency of IFN-γ 
producing CD4 T cells. Moreover, a substantial expansion of CD3+CD4−CD8− T-cell subset expressing 
Vδ2 TCR was specifically observed in ZIKV patients. Vδ2 T cells presented a terminally differentiated 
profile, expressed granzyme B and maintained their ability to produce IFN-γ. These findings provide 
new knowledge on the immune response profile during self-limited infection that may help in vaccine 
efficacy definition, and in identifying possible immuno-pathogenetic mechanisms of severe infection.
Zika virus (ZIKV) is an emerging arbovirus of the Flaviviridae family isolated in Uganda in 19471 and usu-
ally causes a mild and self-limiting infection. Nevertheless, several data strongly indicate a high rate of primary 
microcephaly and Guillain-Barré syndrome during ZIKV infection in French Polynesia and Brazil2–5. There are 
currently no licensed medical interventions (drugs, other therapeutics or vaccines) available to treat or prevent 
ZIKV infection and the development of severe disease. The wide cross reactivity among different flavivirus6 and 
the risk associated with the antibody dependent enhancement7 strongly request the identification of protective 
and pathogenetic immune signature to ZIKV.
ZIKV infects Dendritic cells (DC)8 and antagonizes Type I Interferon Responses, thus subverting DC immu-
nogenicity9. During the acute and convalescent phases of ZIKV infection, increased levels of Th1, Th2, Th9, Th17 
cytokines have been reported, suggesting that a polyfunctional T-cell response is required for recovery from 
ZIKV infection10. Nevertheless, an unbalanced immunoactivation with high levels of IL-6 and IL-8 in the cere-
brospinal fluid has been associated to encephalomyelitis11. Although the main role played by humoral response12, 
an involvement of CD8 T cell response in the protection against ZIKV infection has been recently suggested in 
a mouse model of ZIKV infection13. Moreover, the activation of T-cells and their Th1 polarization has been also 
recently demonstrated in mice14. No data are available on the cellular-mediated immune response during the 
acute phase of ZIKV infection in humans.
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The aim of this study was to study and compare the phenotype and functionality of T-cells in patients with 
acute ZIKV and Dengue viral (DENV) infections.
Results
ZIKV infection expanded CD8 and DN T cells and induced T-cell activation. The characterization 
of T-cell subsets in healthy donors (HD), ZIKV and DENV-infected patients were performed by multiparametric 
flow cytometry (Fig. 1). Representative panels from one HD, one ZIKV- and one DENV-infected patient are 
shown in Fig. 1a. The CD8 T-cells frequency was different in the three groups (Kruskal Wallis, KW < 0.05). In 
particular, when compared to HD, a significant higher CD8 T-cell frequency was observed both in ZIKV- and in 
DENV-infected patients (Fig. 1b). In contrast, no difference in CD4 T-cell frequency was observed among groups 
(Fig. 1c). Finally, the frequency of CD3+CD4−CD8− T-cell population (double negative, DN T-cells) was different 
in the three groups (KW < 0.05). Specifically, a significant expansion of DN T-cells was observed during ZIKV 
infection (Fig. 1d).
The impact of ZIKV infection on T-cell activation was evaluated by analyzing the expression of activation 
markers CD38 and HLA-DR on CD8 (Fig. 2a,b), CD4 (Fig. 2c,d) and on DN (Fig. 2e,f) T-cells. A significant dif-
ference among HD, ZIKV and DENV was observed in the activation profile of CD8 (KW < 0.05) and of CD4 T 
cells (KW < 0.05). Specifically, when compared to HD, a higher frequency of CD38pos and of CD38pos/HLA-DRpos 
CD8 T-cells was observed both in ZIKV and in DENV patients (Fig. 2a). Moreover, a significant higher frequency 
of CD38neg/HLA-DRpos CD8 T-cells was observed in ZIKV-patients than in HD (Fig. 2a). CD4 T-cells showed a 
lower level of activation than CD8 T-cells both in ZIKV and DENV patients but CD38pos CD4 T-cells were signif-
icantly higher in ZIKV and DENV than in HD (Fig. 2c). Although a trend of CD38 increase on DN T cells during 
DENV infection, no significant difference was observed on the activation of DN T-cells among HD, ZIKV and 
DENV, probably due to the small sample size (Fig. 2e).
Figure 1. T-cell subsets during ZIKV infection. Flow cytometric panels of CD3, CD8, CD4 and DN T-cells in 
one representative ZIKV-infected, one DENV-infected patient and in one representative HD (a). The frequency 
of CD8 (b), CD4 (c) and DN (d) T-cells was compared in HD (white bars), ZIKV (grey bars) and in DENV 
(hatched bars). *p < 0.05, **p < 0.01.
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ZIKV infection induced T-cell differentiation. The analysis of the differentiation profile was assessed by 
monitoring the expression of CD45RA and CD27 on CD8 (Fig. 3a,b), CD4 (Fig. 3c,d) and on DN (Fig. 3e,f) T-cells 
allowing to discriminate subsets of naive (N: CD45RAposCD27pos), central memory (CM: CD45RAnegCD27pos), 
effector memory (EM: CD45RAnegCD27neg) and terminally differentiated (TEMRA: CD45RAposCD27neg) T-cells. 
The analysis of CD8 T-cells did not show any difference on the differentiation profile between ZIKV, DENV and 
HD (Fig. 3a). In contrast, a significant difference was observed in the differentiation profile of CD4 (KW < 0.05) 
and DN (KW < 0.05) T-cells. In particular, ZIKV patients showed a lower frequency of CM-CD4 T-cells in com-
parison to both HD and DENV patients, and a parallel higher frequency of EM-CD4 T-cells and TEMRA-CD4 
T-cells in ZIKV respect to HD (Fig. 3c). Similar results were obtained by analysing DN T-cells: indeed, a lower 
frequency of CM-DN T- cells was observed in ZIKV in comparison to both HD and DENV patients and a par-
allel higher frequency of TEMRA-DN T-cells in ZIKV respect to HD (Fig. 3e). Finally, an inverse correlation 
between days after symptoms onset and EM CD8 T-cell frequency was observed (Pearson R: −0.76, R Squared 
0.58, p = 0.04).
ZIKV infection induced the expansion of DN T-cell expressing Vδ2 TCR. To further characterize 
the phenotype of expanded DN T-cells observed during ZIKV infection, the expression of the γδ TCR (Vδ1 
and Vδ2) and CD56 NK marker was analysed by flow cytometry. Results showed that the large majority of DN 
T-cells expressed a Vδ2 TCR (Fig. 4a), suggesting that the DN T-cell population expanded during ZIKV infection 
belongs to the Vδ2 T-cell subset. Accordingly, the frequency of Vδ2 T-cells within CD3 T-cells was significantly 
different among HD, ZIKV and DENV (KW < 0.05). In particular, Vδ2 T-cells was significantly higher in ZIKV 
patients than in HD and in DENV patients (Fig. 4b). Notably, the Vδ2 T-cell expansion was more pronounced 
in patients sampled during the first 2-3 days from symptoms onset [Pt1 and Pt2: Range (23.8–26.6%)] than in 
the other patients sampled after 6 days [Pt3-6: Range (1.5–13.1%)], and an inverse correlation between days after 
symptoms onset and Vδ2 T-cell frequency was observed (Pearson R: −0.84, R Squared 0.70, p = 0.01, Fig. 4c). 
Although not reaching the statistical significance, the analysis of granzyme expression showed a trend of increase 
of Granzyme B positive Vδ2 T-cells in ZIKV patients compared to HD (KW = 0.07, Fig. 4d).
ZIKV infection induced a reduction in IFN-γ production by T-cells. In order to define the functional 
properties of αβ and γδ T-cells during ZIKV infection, we tested their ability to produce cytokines by EliSpot 
assay (Fig. 5a) and flow cytometry (Fig. 5b,e) after mytogenic stimulation. Representative cytometric panels are 
shown (Fig. 5e). As shown in Fig. 5a, a significant reduction in the frequency of IFN-γ producing T-cells was 
observed in ZIKV patients than in HD [ZIKV: median 593 SFC/106PBMC (IQR: 517–620) vs. HD: median 1165 
SFC/106PBMC (IQR: 950–1180), p < 0.05]. We then analysed three different cytokines by flow cytometry, focus-
ing on those that were found elevated in acute ZIKV patients10. The analysis of IFN-γ-producing CD4 T-cells 
Figure 2. Activation of CD8, CD4 and DN T-cells during ZIKV infection. The frequency of activated cells 
(CD38+, CD38+HLADR+, HLADR+) within CD8+ (a), CD4+ (b) and DN (c) T-cells was analyzed by flow 
cytometry in HD (white bars), ZIKV (grey bars) and in DENV (hatched bars). *p < 0.05; **p < 0.01.
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revealed a significant difference among HD, ZIKV and DENV (KW < 0.05). In particular, ZIKV infection was 
associated to a reduction of IFN-γ production by CD4 T-cells (Fig. 5c). Of note, Vδ2 T-cells maintained their 
ability to produce IFN-γ as well as HD and DENV (Fig. 5d). No significant differences were observed in IL-17A 
and IL-2 producing CD4, CD8 and Vδ2 T-cells.
Discussion
The definition of the immunological response to ZIKV infection in humans represents a key issue to identify a 
protective profile useful for vaccine development and for pathogenesis studies. Our study is the first to report the 
dynamics of T-cell profile and function in patients with acute ZIKV infection. There are 4 important findings 
from our study: 1) activation of both CD4 and CD8 T-cells; 2) CD4 T cell differentiation toward effector cells 3) 
substantial expansion of effector Vδ2 T-cells in the first days after symptoms onset 4) cytokine modulation in CD4 
T-cells with a reduction of IFN-γ production.
Activation of CD8 and CD4 T-cells has been extensively described in several viral infections and likely repre-
sents the efforts of the immune system to counteract viral replication. Nevertheless, an excessive T-cell activation 
observed during severe viral diseases such as severe DENV15 or Ebola viral (EBOV) infection16–18 may be harmful 
to the host, by increasing inflammation and promoting anergy of protective T-cells. We found that ZIKV infec-
tion induced a significant activation of CD8 and CD4 T-cells, confirming recent data obtained in mice14. The 
frequency of CD8 T-cells co-expressing both CD38 and HLA-DR was similar in ZIKV and in DENV patients15, 
but was lower than during EBOV infection16, 18, suggesting that a moderate activation may be associated to a 
protective activity and to a mild profile of the disease. In acute infection such as of DENV19 or Ebola virus16–18, the 
activation of T-cells is associated to an increased expression of apoptotic markers. The role of apoptosis during 
ZIKV infection remains to be defined.
The ability of T-cells to differentiate into effectors is a key feature of a protective response. During ZIKV infec-
tion, a CD4 T-cells differentiation towards effectors was described, suggesting the induction of a well coordinate 
immune response. In particular, CD4 T-cells differentiated in effector memory and terminally differentiated cells, 
suggesting the acquisition of a cytokine-producing and cytotoxic profiles. Other study are necessary to deeply 
explore the functional properties of effector CD4 T-cells. An effector phenotype of T-cells was also described in 
the mouse model of ZIKV infection14. Nevertheless, although the expression of an effector phenotype, a signifi-
cant reduction of IFN-γ producing CD4 T-cells was observed respect to both HD and DENV patients. Was can 
speculate that CD4 T-cells during Zika infection were polarized to produce cytokine and chemokines other than 
IFN-γ. The ability of ZIKV to inhibit Type-I IFNs production and response was reported9, 20 but the reduction of 
IFN-γ production by T-cells represent a new finding whose role in the context of protection/pathogenesis needs 
Figure 3. Differentiation profile of CD8, CD4 and DN T-cells during ZIKV infection. The frequency 
of naive (N, CD45RAposCD27pos), central memory (CM, CD45RAnegCD27pos), effector memory (EM, 
CD45RAnegCD27neg) and terminally differentiated (TEMRA, CD45RAposCD27neg) CD8+ (a), CD4+ (b) and DN 
(c) T-cells was analyzed by flow cytometry in HD (white bars), ZIKV (grey bars) and in DENV (hatched bars). 
*p < 0.05; **p < 0.01.
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further investigations. No differences in the frequency of IL-2 and IL-17-producing CD4 and CD8 T-cells was 
observed, suggesting that ZIKV did not modify the ability of T-cells to produce these cytokines that indeed were 
found higher in the sera of ZIKV patients10.
The current study reports for the first time a substantial expansion of Vδ2 T-cells during ZIKV infection, that 
was more pronounced during the first days from symptoms onset. Expanded Vδ2 T-cells presented an effector 
phenotype and expressed granzyme B. A pillar role of Vδ2 T-cells in a well orchestrated immune response to viral 
infection is well documented21. Indeed, human γδ T-cells may affect the progression and outcome of infectious 
diseases22, 23. Activated Vδ2 T-cells are able to exert direct antiviral activities and to perform several stimulatory 
activities on both innate and adaptive immune cells24–27. Several reports suggest a protective role of γδ T-cells 
during other acute viral infections22, 23, 28–30. γδ T-cells expand quickly in response to WNV infection, produce 
significant amount of IFN-γ, limiting the viral load and protecting the host from lethal encephalitis29, 30. We 
could not directly correlate the Vδ2 T-cell expansion with a protective effect during ZIKV infection, since all the 
patients included in this study showed a mild clinical course of the disease and no sequelae were observed. A 
direct comparison between severe and mild diseases may be helpful in supporting a protective role of γδ T-cells 
during ZIKV infection. The analysis of Vδ2 T-cells may also be important to better understand the pathogene-
sis associated with severe clinical complications of ZIKV infection such as microcephaly in foetuses2, 3 and/or 
Guillain Barré syndrome in adults31. Interestingly, an expansion of Vδ2 T-cells has been associated with recurrent 
abortions32, 33. Furthermore, the Th1 profile of expanded Vδ2 T-cells might contribute to placenta damage and/or 
inflammation that has been correlated with foetal brain damage during ZIKV infection34. Finally, γδ T-cells may 
play a role during autoimmune diseases35 and in particular during Guillain Barré syndrome36–38, contributing to 
autoimmune damage.
Figure 4. The expanded DN T-cells express Vδ2 TCR. Flow cytometric panels showing the expression of Vδ1-
TCR, Vδ2 TCR and CD56 marker on DN T-cells are shown (a). The frequency of Vδ2 within CD3 T-cells (b) 
was compared in HD (white bars), ZIKV (grey bars) and in DENV (hatched bars). The correlation between time 
after sympthoms onset (days) and the Vδ2 T cell frequency (c) during Zika infection is shown. The frequency of 
granzyme positive Vδ2 T cells (d) was compared in HD (white bars), ZIKV (grey bars) and in DENV (hatched 
bars). *p < 0.05.
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In summary, this study shows for the first time the activation of both CD8 and CD4 T-cell subsets, a reduction 
of IFN-γ producing CD4 T-cells and a prolific expansion of effector Vδ2 T-cells during acute ZIKV infection. 
Further studies on a larger sample size (including mild and severe ZIKV-associated diseases) are required to 
clarify the role of the Vδ2 T-cells and of reduced IFN-γ production by CD4+ T-cells in the protection and/or 
pathogenesis of ZIKV infection and to help develop rational strategies for new vaccine and therapeutics.
Figure 5. Functional profile of CD8 and CD4 T-cells response to ZIKV infection. IFN-γ production by T-cells 
after PHA stimulation was analyzed by EliSpot assay (a). The frequency of CD8 (b), CD4 (c) and Vδ2 (d) T-cells 
producing IL-17A, IL-2 and IFN-γ after PMA/Ionomycin stimulation is shown in ZIKV (red bars), DENV 
(green bars) and HD (blue bars). *p < 0.05.
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Materials and Methods
Ethical Approval. The study was approved by the National Institute for infectious Diseases (INMI), L 
Spallanzani of Rome Ethics Committee (approval number: 14/2015) and all patients gave written informed con-
sent. All methods were performed in accordance with the relevant guidelines and regulations.
Patients enrolled. Patients returning from travel in Latin America, in India or Southeast Asia (Table 1) were 
enrolled at the National Institute for infectious Diseases (INMI), L Spallanzani of Rome (in travel clinic) after 
diagnosis of ZIKV or DENV infections. Specifically, 7 Italian patients (6 females and 1 male; median age 41.2 
years) were positive for ZIKV (both serology and PCR), and 5 Italian patients (2 females and 3 males; median age: 
48.5 years) were positive for DENV (both serology and PCR). 10 healthy donors (HD) were enrolled as controls. 
The main manifestations of ZIKV and DENV are summarized in Table 1. The serological and virological data are 
reported in Table 2.
Serological and virological assays. Whole-blood samples were collected using sterile EDTA-treated 
Vacutainer tubes (Becton Dickinson). The ZIKV and DENV diagnosis was performed by using both molec-
ular and serological tests and other arboviral infections (Chikungunya virus) were ruled out. Serum samples 
were tested by indirect immunofluorescence assay for both IgM and IgG antibodies against ZIKV, DENV and 
Chikungunya virus (CHIKV) (IFA Arboviral Fever Mosaic 2 IgM and IgG Euroimmun AG, Luebeck, Germany). 
Serum, saliva and urine samples from patients were tested also by Real Time RT-PCR for ZIKV, DENV and 
CHIKV RNA39–41.
Leucocytes isolation and flow cytometry. Peripheral Blood Mononuclear Cells (PBMC) were isolated 
by Ficoll procedure, counted and stored at −80 °C in 90% FCS/10% DMSO (Euroclone). Cryopreserved PBMC 
were rapidly thawed, washed with PBS 1X and analyzed by flow cytometry using the following anti-human 
monoclonal antibodies to assess T-cell subsets, and T-cell activation, differentiation and functional profile: CD4 
V450 (Clone RPA-T4), CD8 APC H7 (Clone SK1), CD8 Pe Cy 7 (Clone RPA T8), CD3 PerCp Cy 5.5 (Clone SP 
34-2), CD3 FITC (Clone UCHT1), CD3 V500 (Clone UCHT1), CD27 APC H7 (Clone M-T271), CD38 APC 
(Clone HIT2), HLA-DR PerCp (Clone L243), Vδ2 TCR PE (Clone B6), INF-γ PE-Cy 7 (Clone B27), Vδ2 TCR 
FITC (Clone B6), Granzyme –B AlexaFLUOR647 (Clone GB11), CD45 AmCyan (Clone 2D1), purchased from 
BD Pharmigen; CD45RA PerCp-Vio 700 (Clone REA 562), IL 2 APC (Clone N7.48 A), purchased from Macs 
Miltenyi Biotec; TCR Delta TCδ1 FITC (Clone TS-1), purchased from ThermoFisher Scientific; CD56 (Clone 
N 901), purchased from Beckman Coulter; and finally, IL-17A PE (Clone eBio64CAP17), purchased from 
Affymetrix eBioscience. Briefly, 5 × 105 PBMC were incubated for 15 min at 4 °C with the indicated mAbs. After 
washing (PBS/1%BSA/0.1% sodium azide), samples were fixed with 2% paraformaldehyde (Electron Microscopy 
Sciences) and immediately acquired using a FACSCanto II flow cytometer. The general gating strategy was: 
FSC-A v. SSC-A > CD3pos > CD4 pos or CD8 pos or CD4 negCD8 neg cells. The activation analysis was per-
formed by analyzing CD38 and HLA-DR expression on i) CD4 pos, ii) CD8 pos and iii) CD4 negCD8 neg cells. 
The differentiation profile was performed by analyzing CD27 and CD45RA on i) CD4 pos, ii) CD8 pos and iii) 
CD4 negCD8 neg cells. The gating strategy for the analysis of CD3posCD4 negCD8 neg cells was: FSC-A v. 
SSC-A > CD3pos > CD4 negCD8 neg cells > Vδ1 or Vδ2 or CD56. The gating strategy for the analysis of Vδ2 T 
cells was: FSC-A v. SSC-A > CD3pos > Vδ2 T cells > Granzyme B. Positive gates were selected on the basis of 
isotype matched controls. Results are shown as Box and Whiskers: the box encompasses the interquartile range of 
individual measurements, the horizontal bar-dividing line indicates the median value, and the whiskers represent 
maximum and minimum values.
Elispot assay. T-cell functionality during Zika acute infection was assessed by detecting interferon-gamma 
(IFN-γ) production using an enzyme-linked immunosorbent spot-forming cell assay (ELISpot) after PHA stim-
ulation. Peripheral blood mononuclear cells (PBMCs) were thawed in culture medium (RPMI 1640, 10% FCS, 
2 mmol/liter L-glutamine) and assessed for vitality by Trypan Blue exclusion, counted, and plated at 3 × 105 cells/
well in ELISpot plates (AID GmbH, Strabberg, Germany). PBMCs were then stimulated with PHA, included in 
the Elispot kit, for 24 hours with 5% of CO2. At the end of incubation, the ELISpot assay was developed accord-
ing to manufacturer’s instructions. Spontaneous cytokine production (background) was assessed by incubat-
ing PBMC with 1 μg/ml αCD28 and αCD49d (IgG1, clones CD28.2 and 9f10, respectively; Becton Dickinson, 
Mountain View, CA). Results are expressed as spot forming cells (SFC)/106 PBMCs in stimulating cultures after 
subtracting spontaneous background.
Patients (n° pts)
Gender 
(M/F) Age Travel History (n° pts)
Symptoms onset 
(range, days) Symptoms
ZIKV (7) 1/6 37 ± 9.7 Brazil (2) Mexico (2) Barbados (3) 2–9
cutaneous rash: 7/7 
fever: 4/7 headache: 
3/7 arthralgia: 6/7
DENV (5) 2/3 45.2 ± 14.7 Brazil (1) Indonesia (2) Vietnam (1) India (1) 4–9
cutaneous rash: 4/5 
fever: 4/5 headache: 
0/5 arthralgia: 4/5
Table 1. Clinical features of enrolled patients.
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Polyfunctional analysis. Cytokines and chemokines expression were simultaneously examined by using 
multiparametric flow cytometry. Briefly, PBMCs from ZIKV infected patients and from healthy donors were 
stimulated for 4 hours with PMA/Ionomycin (PMA 50 nM/ml and Ionomycin 1μM/ml, Sigma Aldrich) for 
CD4 T-cells, and IPH 1101 (3 μM, Innate Pharma, Marseille, FR) for Vδ2 T-cells. Brefeldin A (10 μg/ml, Serva) 
was added after 1 hour of stimulation. First, surface staining was performed using anti-human CD3, anti-CD4, 
anti-CD8 and anti- Vδ2 conjugated monoclonal antibodies prepared using PBS/BSA/NAN3 solution. After an 
incubation of 10 minutes at 4 °C, cells were washed and fixed with 2% paraformaldehyde (Electron Microscopy 
Sciences) and then stained for intracellular cytokines using anti-human IFN-γ, IL-2, IL-17A conjugated mon-
oclonal antibodies prepared using a solution of PBS/BSA/NAN3 with 0.5% saponin. After an incubation of 
20 minutes, cells were washed and acquired on FACSCanto II (BD, Buccinasco, Milano, Italy) flow cytometer 
and analyzed using Diva (BD) and FlowJo Softwares (TreeStar, Olten, Switzerland). Results are shown as Box and 
Whiskers: the box encompasses the interquartile range of individual measurements, the horizontal bar-dividing 
line indicates the median value, and the whiskers represent maximum and minimum values.
Patient ID 
(Gender)
Days after 
symptoms 
onset Sample
ZIKV Real 
Time RT-
PCRa
DENV Real 
Time RT-
PCRb
CHIKV Real 
Time RT-
PCRc
Anti 
ZIKV 
IgGd
Anti 
ZIKV 
IgMd Anti DENV IgGd Anti DENV IgMd
Anti 
CHIKV 
IgGd
Anti 
CHIV 
IgMd
Pt1 (F) 3
Serum Negative Negative Negative 1:320 <1:20 1:640 <1:20 <1:20 <1:20
Urine Positive Negative ND ND ND ND ND ND ND
Saliva Positive Negative ND ND ND ND ND ND ND
Pt2 (F) 2
Serum Positive Negative Negative <1:20 <1:20 <1:20 <1:20 <1:20 <1:20
Urine Positive Negative ND ND ND ND ND ND ND
Saliva Negative Negative ND ND ND ND ND ND ND
Pt3e (F) 9
Serum Negative Negative Negative 1:160 1:80 1:40 <1:20 <1:20 <1:20
Urine Positive Negative ND ND ND ND ND ND ND
Pt4 (M) 9
Serum Negative Negative Negative 1:80 1:160 1:20 <1:20 <1:20 <1:20
Urine Positive Negative ND ND ND ND ND ND ND
Saliva Negative Negative ND ND ND ND ND ND ND
Pt5 (F) 9
Serum Positive Negative Negative 1:160 1:80 1:160 <1:20 <1:20 <1:20
Urine Positive Negative ND ND ND ND ND ND ND
Saliva Negative Negative ND ND ND ND ND ND ND
Pt6 (F) 6
Serum Negative Negative Negative 1:20 1:80 <1:20 <1:20 <1:20 <1:20
Urine Positive Negative ND ND ND ND ND ND ND
Saliva Negative Negative ND ND ND ND ND ND ND
Pt7 (F) 9
Serum Negative Negative Negative 1:160 1:80 <1:20 <1:20 <1:20 <1:20
Urine Positive Negative ND ND ND ND ND ND ND
Saliva Negative Negative ND ND ND ND ND ND ND
Pt8 (M) 9
Serum Negative Positive Negative <1:20 <1:20 Weak reactivity 1:40 <1:20 <1:20
Urine Negative Positive ND ND ND ND ND ND ND
Saliva Negative Negative ND ND ND ND ND ND ND
Pt9 (M) 4
Serum Negative Positive Negative <1:20 <1:20 <1:20 <1:20 <1:20 <1:20
Urine Negative Negative ND ND ND ND ND ND ND
Saliva Negative Negative ND ND ND ND ND ND ND
Pt10 (M) 5
Serum Negative Positive Negative <1:20 1:40 1:40 1:80 <1:20 <1:20
Urine Negative Positive ND ND ND ND ND ND ND
Saliva Negative Negative ND ND ND ND ND ND ND
Pt11 (F) 5
Serum Negative Positive Negative <1:20 <1:20 <1:20 Weak reactivity <1:20 <1:20
Urine Negative Positive ND ND ND ND ND ND ND
Saliva Negative Positive ND ND ND ND ND ND ND
Pt12 (F) 4
Serum Negative Positive Negative <1:20 <1:20 1:40 <1:20 <1:20 <1:20
Urine Negative Negative ND ND ND ND ND ND ND
Saliva Negative Negative ND ND ND ND ND ND ND
Table 2. Serological and virological data of ZIKV- and DENV-infected patients. DENV: dengue virus; ZIKV: 
Zika virus; RT-PCR: Reverse transcription polymerase chain reaction; ND: not done. aZIKV specific Real 
Time RT-PCR39. bCDC DENV-1–4 Real-Time RT-PCR Assay for Detection and Serotype Identification 
of Dengue Virus38. cCHIKV Real-Time RT-PCR Assay targeting the E1 structural protein40. dIgG and IgM 
indirect immunofluorescence assay Euroimmun Flavivirus Mosaic 2. Reference values (titre): <1:20 = negative; 
≥1:20 = positive. eThis patient is vaccinated against Yellow Fever.
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Statistical analyses. Statistical significance was determined by GraphPad Prism software. The differ-
ences in the median values among multiple groups (HD, ZIKV and DENV) were evaluated by non-parametric 
Kruskall-Wallis (KW) test. The differences in the median values between two groups were evaluated by 
non-parametric Mann-Whitney test. A p–value < 0.05 was considered significant.
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